ISSN: 1859 - 2872
Early response of stereotactic body radiation therapy in stage I non-small cell lung cancer patients
Main Article Content
Keywords
Abstract
Objective: To evaluate the early response of SBRT in stage I NSCLC patients (T1-T2aN0M0). Subject and method: Prospective, follow-up 25 patients with stage T1-T2aN0M0 NSCLC, who were received SBRT and evaluated every three months from January, 2015 to December, 2020. The response in third month was assessed according to RECIST 1.1 and PERCIST 1.0, the toxicity was evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03/2010. Result: The average age was 65.32 years-old, the mean of diameter on the Chest CT was 3.33cm, on the PET/CT 3.21cm, the mean of FDG value was 8.01. The stage of the tumor was mostly T2a (56%). Patients were indicated SBRT due to COPD: 60%. The mean of the doses was 4208cGy, 40% of patients was treated by 1 fraction, others were 3 - 5 fractions. According to RECIST criteria, no patients completion response (CR), 44% partial response (PR), 36% stable disease (SD) and 5 patients progression disease (PD), the objective response rate (ORR) was 44%, the disease control rate (DCR) was 80%. By PERCIST, there was 1 patient CR, the others ratios were 68%, 24%, 8%, 68% and 92%, respectively, the difference between two criteria was statistically significant (p<0.05). CEA and SUVmax value were related to the response after treatment (p<0.05). The common of adverse events was pneumonitis due to SBRT at 11 patients, but mainly was grade 1, no patients had pneumonitis grade 4 and 5. No clinically significant changes in pulmonary function following SBRT for early stage NSCLC. Conclusion: SBRT was the treatment for a good response in stage I NSCLC patients with a disease control rate of 92%, and was a safe treatment for patients.
Article Details
References
2. Jessica D, Mark F, Peter M et al (2012) American college of chest physicians and society of thoracic surgeons consensus statement for evaluation and management for high-risk patients with stage I Non-small cell lung cancer. Chest 142(6): 1620-1635.
3. Bryan JS, Megan ED, Erin BK et al (2017) Stereotactic body radiation therapy for early-stage non-small cell lung cancer: American Society for Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol 36: 710-719.
4. Ashwin S, Richard L, Jae K et al (2018) Stereotactic body radiation therapy (SBRT) for early stage lung cancer in the elderly. Seminars in Oncology 45: 210-219.
5. Achilles JF, Ronald CM, Constaitin TY et al (2009) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: Four-year results of a Prospective Phase II Study. Int J Radiat Oncol Biol Phys 75(3): 677-682.
6. Hiroshi O, Tsutomu A, Hiroki S et al (2004) Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101(7): 1623-1631.
7. Robert T, Rebecca P, Jame G et al (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11): 1070-1076.
8. Nagata Y, Hiraoka M, Shibata T et al (2012) Stereotactic body radiation therapy for T1N0M0 non-small cell lung cancer first report for inoperable population of a phase II trial by Japan Clinical Oncology Group (JCOG 0403). Int J Radiat Oncol Biol Phys 84: 46.
9. Umberto R, Andrea RF, Alessia G et al (2010) Stereotactic body radiation therapy for early stage non-small cell lung cancer: Results of a prospective trial. Lung cancer 68(1): 72-77.
10. Pia B, Jan N, Morten H et al (2009) Outcome in a prospective phage II trial of medically inoperable stage I non-small cell lung cancer patients treated with stereotactic body radiation therapy. J Clin Oncol 27: 3290-3296.
11. Gregory MM Videtic, Jessica D, Meredith Giuliani et al (2017) Steraotactic body radiation therapy for early stage non-small cell lung cancer: An ASTRO evidence-based Guideline. Practical Radiation Oncology.
12. Vansteenkiste J, Crino L, Douillard JY et al (2014) 2nd ESMO Consensus conferencer on lung cancer: Early stage non-small cell lung cancer consensus ondiagnosis, treatment and follow-up. Annals of Oncology 00: 1-13.
13. Alex KB, Robert CM, Ajay PS et al (2018) Stereotactic body radiation therapy versus surgery for early lung cancer among US Veterans. Ann Thorac Surg 105: 425-31.
14. Yuta S, Chisa H, Fumiya B et al (2012) Stereotactic body radiation therapy using a radiobiology-based regimen for stage I non-small cell lung cancer, a muticenter study. Cancer: 2078-2084.
15. Luca N, Chiara R, Linda A et al (2019) Long term results of singele high dose steraotactic nody radiation therapy in the treatment of primary lung tumors. Scientific report 9: 15498.
16. Michael CR, Cliff GR, Todd AD et al (2018) Stereotactic body radiation therapy for central early stage NSCLC: Results of a Prospective Phase I/II trial. Journal of Thoracic Oncology 13(11): 1727-1732.
17. Atsuya T, Naoko S, Hirofumi F et al (2014) Maximim Standardized Uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small cell lung cancer patients after Stereotactic Body Radiationtherapy. J Thorac Oncol 9: 65-73.
18. William AS, Michael RB, Robert AM et al (2018) Post-treatment mortality after surgery and Stereotactic Body Radiation Therapy for early- stage Non-small cell lung cancer. J Clin Oncol 36: 642-651.
19. Stanic S, Paulus R, Timmerman RD et al (2014) No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys 88(5): 1092-1099.
20. Bishawi M, Kim B, Moore WH, Bilfinger TV (2012) Pulmonary function testing after stereotactic body radiotherapy to the lung. Int J Radiat Oncol Biol Phys 82(1): 107–110.
Article Sidebar
